Mr. Thomas O'Shaughnessy reports

ONCO-INNOVATIONS SIGNS AGREEMENT WITH REDWOOD AI TO ADVANCE DISCOVERY AND EVALUATION OF ITS PNKP INHIBITOR TECHNOLOGY

Onco-Innovations Ltd. has entered into a service agreement with Redwood AI Inc. This collaboration marks continued advancement of Onco's mission to accelerate the development of its exclusively licensed polynucleotide kinase phosphatase compound and to extend its proprietary knowledge through discovery. This proprietary compound aims to target a range of solid tumours by enhancing sensitivity to radiation and DNA-damaging chemotherapies, offering the potential to exploit specific genetic susceptibilities in cancer. Through this agreement with Redwood AI, Onco gains access to Redwood AI's artificial-intelligence-driven chemistry tools that have the potential to unlock critical efficiencies in drug development, thereby carrying the potential to reduce synthesis complexity, refine compound design and expand the pipeline of viable analogues. This effort is aimed at reinforcing Onco's technical capabilities at a crucial preclinical phase, with the goal of improving scalability, safety and discovery precision.

Under the scope of the agreement, Redwood AI will provide multipronged support across synthesis evaluation, cheminformatics, and organ-specific toxicity prediction for the technology and its structural analogues. This includes independent reviews of third party chemistry proposals and the use of Redwood's proprietary in-silico modelling tools. In simpler terms, these efforts are intended to deepen Onco's understanding of its technology by supporting structure-based refinement and mechanistic insight. These efforts are part of Onco's broader strategy to efficiently progress toward first-in-human studies.

Redwood AI is a Vancouver-based artificial intelligence company harnessing artificial intelligence to accelerate drug synthesis and development. Founded by a team with deep roots in chemistry, AI and drug manufacturing, including origins from Stanford, Redwood AI is focused on overcoming one of the pharmaceutical industry's most persistent challenges: drug synthesis. By automating a substantial portion of the traditionally manual steps involved in synthesis, Redwood's technology aims to support more accurate, scalable and cost-effective drug creation, with the goal of helping research teams move from discovery to development faster and with greater efficiency.

"The pace of innovation in cancer therapeutics depends on how quickly we can turn complex data into actionable decisions. Redwood AI's platform has the potential to enable us to explore synthesis strategies, evaluate risks and optimize compound design with greater speed and precision. This kind of insight not only strengthens our scientific direction but also has the potential to accelerate our timeline towards clinical trials," stated Thomas O'Shaughnessy, chief executive officer of Onco-Innovations.

About Onco-Innovations Ltd.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide licence to patented technology that targets solid tumours.

We seek Safe Harbor.